跳至主要内容
临床试验/NCT03780062
NCT03780062已完成3 期

Interest of S100B Protein for Patient Victim of Minor Traumatic Brain Injury and Treated by Antiplatelet

Poitiers University Hospital4 个研究点 分布在 1 个国家目标入组 720 人开始时间: 2019年1月25日最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
入组人数
720
试验地点
4
主要终点
Brain scanner Detection of a cerebral lesion requiring a surgery or medical intervention or an hospitalisation for a patient who have serum level of S100B protein with the treshold of 0.105 μg/L

研究概览

简要总结

All the patients admitted in emergency department for minor traumatized cranial, with antiplatelet therapy, can be included, after checked inclusion and non inclusions criterias. If they are agree, a blood sample for the dosage of S100b will be done.

No other modification of the medical care, all patients will have tomodensitometria, according with recommendations. The aim of the study is to validate the negative predictive value of S100b in this population.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age > 18 Years old
  • Minor traumatic brain injury measured by a Glasgow score between 13 and 15
  • Antiplatelet agent therapy
  • Free subject without tutorship or curatorship

排除标准

  • Age < 18 years old
  • Glasgow score <13
  • Traumatic brain injury older than 6 hours
  • Patient without any social security system
  • Patient with renforced protection (tutorship, curatorship, …)

研究组 & 干预措施

S100B protein dosing

Experimental

干预措施: S100B protein dosing (Biological)

结局指标

主要结局

Brain scanner Detection of a cerebral lesion requiring a surgery or medical intervention or an hospitalisation for a patient who have serum level of S100B protein with the treshold of 0.105 μg/L

时间窗: 3 hours

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验